Effects of azathioprine withdrawal in kidney recipients with stable function two years after transplant

Clinical Transplantation

Volumn 10, Issue 6 II, 1996, Pages 617-619

  Goldman, Mitchell H ^a,b   Davis, Brooks ^a   Cruz, Edgar ^a   Miller, Patricia ^a   Stevens, Scott L ^a   Freeman, Michael B ^a   Tyler, John D ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b UTMCK   (United States)

Author keywords

Azathioprine; Immunosuppression; Renal transplantation

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CADAVER KIDNEY; CLINICAL PROTOCOL; CONTROLLED STUDY; DIALYSIS; DRUG WITHDRAWAL; HEMATOCRIT; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECIPIENT;

AZATHIOPRINE; CHRONIC DISEASE; GRAFT REJECTION; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 0030448324     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BERGAN S, RUGSTAD HE, BENTDAL O, STOKKE O. Monitoring of azathioprinetreatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes. Transplantation 1994: 58: 803.
2. GAYA SBM, REES AJ, LECHLER RI, WILLIAMS G, MASON PD. Malignant disease in patients with long-term renal transplants. Transplantation 1995: 59: 1705.
3. KEHINDE EO, PETERMANN A, MORGAN JD, et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994: 81: 985.
4. SAGALOWSKY AI, REISMAN MD, DAVIDSON I, TOTO R, PETERS PC, HELDERMAN JH. Late cyclosporine conversion carries risk of irreversible rejection. Transpl Proc 1988: 20: 157.
5. MAIORCA R, CRISTWELL L, BRUNORI G. et al. Prospective controlled trial of steroid withdrawal after 6 months in renal transplant patients treated with cyclosporine. Transpl Proc 1988: 20:121.
6. STARZL TE, DEMETRIS AJ, TRUCCO M, et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993: 55: 1272.
7. KELLY GE, MEIKLE WD, MOORE DE. Enhancement of UV-induced skin carcmogenesis by azathioprine: role of photochemical sensitization. Photochem Photobiol 1989: 49: 59.
8. DALTON A, CURTIS D. HARRINGTON CI. Synergistic effects of azathioprine and ultraviolet light detected by sister chromatid exchange analysis. Cancer Genet Cytogenet 1990: 45: 93.
9. TAYLOR AEM, SHUSTER S. Skin cancer after renal transplantation. The causal role of azathioprine. Acta Derm Venereol 1992: 72: 115.
10. BUNNEY MH, BENTON EC, BARR BB, SMITH IW, ANDERTON JL, HUNTER JA. The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. Nephrol Dial Transpl 1990: 5: 379.
11. CONNELL WR, KAMM MA, DICKSON M, BALKWILL AM, RITCHIE JK, LENNARD-JONES JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994: 343: 1249.
12. AMATO MP, PRACUCCI G, PONZIANI G, SIRACUSA G, FRATIGLIONI L, AMADUCCI L. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993: 43: 831.
13. COHEN LM, TYRING SK, RADY P, CALLEN JP. Human paillomavirus type II in multiple squamous cell carcinomas in a patient with subacute cutaneous lupus erythematosus. J Am Acad Dermatol 1992: 26: 840.
14. MION F, NAPOLEON B, BERGER F, CHEVALLIER M, BONVOISIN S, DESCOS L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the iiver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991: 32: 715.
15. HORSMANS Y, RAHIER J, GEUBEL AP, Reversible cholestasis with bile duct injury following azathioprine therapy. A case report. Liver 1991: 11:89.
16. HABOUBI NY, ALI HH, WHITWELL HL, ACKRILL P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 1988: 83: 256.
17. PERINI GP, BONADIMAN C, FRACCAROLI GP, VANTTNI I. Azathioprine-relatedcholestatic jaundice in heart transplant patients. J Heart Transpl 1990: 9: 577.
18. STERNECK M, WFESNER R, ASCHER N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991: 14: 806.
19. LORENZ R, BRAUER M, CLASSEN M, TORNIEPORTH N, BECKER K. Idiopathic portal hypertension in a renal transplant patient after long-term azathioprine therapy. Clin Investig 1992: 70: 152.
20. WAGONER LE, OLSEN SL, BRISTOW MR, et al. Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine-induced hepatotoxicity. Transplantation 1993: 56: 1415.
21. AGARWAL SK, MITTAL D, TIWARI SC, et al. Azathioprine-induced pure red blood cell aplasia in a renal transplant recipient. Nephron 1993: 63: 471.
22. CREEMERS GJ, VAN BOVEN WP, LOWENBERG B, VAN DER HEUL C. Azathioprine-associated pure red cell aplasia. J Intern Med 1993: 233: 85.
23. VOGT B, FIVUSH BA. Cyclosporine in the treatment of azathioprine-induced red cell aplasia following renal transplantation. Pediatr Nephrol 1992: 6. 278.
24. CONNELL WR, KAMM MA, RITCHIE JK, LENNARD-JONES JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993: 34: 1081.
25. KARMI SA, DEPALMA R, BOSCH J, DOSA S, MICHELL A. An update on the use of low-dose maintenance cyclosporine a therapy after renal transplantation. Transpl Proc 1988: 20.114.
26. HIESSE C, ROUSSEAU P, KRIAN F, LARUE JR, CHARPENTIER B. Elective versus systemic corticosteroid withdrawal in renal transplant recipients receiving triple drug therapy. Transpl Proc 1995: 27:1066.